Furthermore, HER2-mediated delivery of MM-302 to HER2-overexpressing tumor cells was confirmed in multiple evaluable biopsies post-MM-302 treatment by co-localization of anti-PEG, anti-HER2, and anti-cytokeratin antibodies (Fig. 3g). This evidence concerns the gene ERBB2 and neoplasm.